+ Follow SANOFI-SYNTHELABO AND CEPHALON Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 147972
[Title] => Sanofi-Synthelabo and Cephalon ink agreement
[Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2002-01-22 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[1] => Array
(
[ArticleID] => 147162
[Title] => Sanofi-Synthelabo and Cephalon ink agreement
[Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2002-01-15 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[2] => Array
(
[ArticleID] => 146353
[Title] => Sanofi-Synthelabo and Cephalon ink agreement
[Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2002-01-08 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[3] => Array
(
[ArticleID] => 145603
[Title] => Sanofi-Synthelabo and Cephalon ink agreement
[Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2002-01-01 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[4] => Array
(
[ArticleID] => 145286
[Title] => Sanofi-Synthelabo and Cephalon ink agreement
[Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2001-12-29 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
)
)
SANOFI-SYNTHELABO AND CEPHALON
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 147972
[Title] => Sanofi-Synthelabo and Cephalon ink agreement
[Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2002-01-22 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[1] => Array
(
[ArticleID] => 147162
[Title] => Sanofi-Synthelabo and Cephalon ink agreement
[Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2002-01-15 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[2] => Array
(
[ArticleID] => 146353
[Title] => Sanofi-Synthelabo and Cephalon ink agreement
[Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2002-01-08 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[3] => Array
(
[ArticleID] => 145603
[Title] => Sanofi-Synthelabo and Cephalon ink agreement
[Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2002-01-01 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[4] => Array
(
[ArticleID] => 145286
[Title] => Sanofi-Synthelabo and Cephalon ink agreement
[Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2001-12-29 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
)
)
abtest
January 22, 2002 - 12:00am
January 15, 2002 - 12:00am
January 8, 2002 - 12:00am
January 1, 2002 - 12:00am
December 29, 2001 - 12:00am
